April 29, 2025 2:35 PM

Novel CAR-T therapy shows promise against hard-to-treat cancer

A novel CAR-T cell therapy developed by a team of Brazilian researchers has shown promising results in treating a particularly stubborn form of lymphoma—one that affects the lymph nodes, spleen, and bone marrow and is often resistant to existing treatments. Named HSP-CAR30, the therapy targets the CD30 protein and has successfully completed its initial Phase I trial, becoming the first European CAR-T30 study to reach this milestone. The findings, published in the journal Blood, indicate high ...